ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 45 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $612,265 | +18.6% | 53,473 | +6.5% | 0.00% | – |
| Q2 2023 | $516,097 | +139.5% | 50,204 | +79.9% | 0.00% | – |
| Q1 2023 | $215,496 | +67.0% | 27,914 | +59.0% | 0.00% | – |
| Q4 2022 | $129,073 | +53.7% | 17,561 | +51.9% | 0.00% | – |
| Q3 2022 | $84,000 | -25.0% | 11,562 | -12.4% | 0.00% | – |
| Q2 2022 | $112,000 | +34.9% | 13,199 | +42.3% | 0.00% | – |
| Q1 2022 | $83,000 | -34.6% | 9,277 | +1.4% | 0.00% | – |
| Q4 2021 | $127,000 | +353.6% | 9,145 | +234.5% | 0.00% | – |
| Q3 2021 | $28,000 | -6.7% | 2,734 | -17.8% | 0.00% | – |
| Q2 2021 | $30,000 | -47.4% | 3,326 | -37.8% | 0.00% | – |
| Q1 2021 | $57,000 | -98.8% | 5,350 | -98.6% | 0.00% | -100.0% |
| Q4 2020 | $4,759,000 | +22561.9% | 377,723 | +15527.8% | 0.00% | – |
| Q3 2020 | $21,000 | -47.5% | 2,417 | -40.7% | 0.00% | – |
| Q2 2020 | $40,000 | – | 4,075 | +58114.3% | 0.00% | – |
| Q1 2020 | $0 | – | 7 | -66.7% | 0.00% | – |
| Q4 2019 | $0 | – | 21 | -16.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 25 | -99.6% | 0.00% | – |
| Q2 2019 | $29,000 | -35.6% | 6,879 | +5.2% | 0.00% | – |
| Q1 2019 | $45,000 | +55.2% | 6,538 | -14.9% | 0.00% | – |
| Q4 2018 | $29,000 | +314.3% | 7,684 | +641.0% | 0.00% | – |
| Q3 2018 | $7,000 | -12.5% | 1,037 | 0.0% | 0.00% | – |
| Q2 2018 | $8,000 | -27.3% | 1,037 | -28.1% | 0.00% | – |
| Q1 2018 | $11,000 | -8.3% | 1,443 | +39.2% | 0.00% | – |
| Q4 2017 | $12,000 | -58.6% | 1,037 | -59.1% | 0.00% | – |
| Q3 2017 | $29,000 | – | 2,537 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |